Navigation Links
MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
Date:6/28/2008

ing the receptor pharmacology data entitled "Improved Dihydroergotamine (DHE) Pharmacology Following Orally-Inhaled Delivery." In addition to this study, the Company presented five posters relating to the MAP0004 program, including:

-- Newer Acute Migraine Specific Drugs May Provide Improved Sustained Relief and Freedom Over 24 and 48 Hours Post Dosing

-- Chronic Inhalation Toxicological Assessment of Dihydroergotamine in Dogs

-- Assessment of QTc Effect of DHE When Delivered Via the Lung by the Tempo Inhaler

-- MAP0004, an Orally Inhaled Formulation of DHE, Delivers Faster and More Consistent Blood Levels of the Drug Compared to Traditional Oral, Subcutaneous, Intramuscular, and Intranasal Formulations of DHE

-- Systemic Pharmacokinetics of DHE When Delivered Via the Lung to Asthmatics by the Tempo Inhaler

About MAP0004

MAP0004 is a proprietary orally inhaled version of dihydroergotamine, or DHE, intended to treat migraine. In the Company's Phase 2 efficacy study, MAP0004 provided pain relief as early as within ten minutes of dosing, and this relief was sustained through at least 24 hours. The study also demonstrated efficacy trends in treating nausea, photophobia and phonophobia. Based on these results, as well as independent research that concludes that patients prefer migraine therapies providing fast onset, pain relief, sustained pain relief and safety, the Company believes that MAP0004 has the potential to be a first-line therapy for migraine patients. Historically, estimated onset of significant pain relief with oral triptans, the class of drugs most often prescribed for treating migraine, occurs between 45 and 90 minutes after dosing. In 2007, triptans generated sales of approximately $2.2 billion in the United States, according to data published by IMS Health.

MAP0004 is designed to be an easy to use, non-invasive, at-home therapy that patients self-administer using the Company's proprietary hand-held
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
2. Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis
3. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
4. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
5. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
6. Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting
7. Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
8. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
9. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
10. Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
11. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)...  PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results ... June 30, 2014. Quarter Ended June ... 30, 2014 increased $492,000, or 18%, to $3.2 million ... 30, 2013, due primarily to an increase of $746,000 ... Company,s largest customer, partially offset by an aggregate decrease ...
(Date:9/18/2014)... Texas , Sept. 18, 2014  Casen Buswell has ... and muscles to harden.  His case is one of only ... the world.  The only hospital in the United ... the world, offering treatment with the dual wave-length laser, is ... San Antonio . Using a laser available in ...
(Date:9/18/2014)... PHILADELPHIA and LONDON ... new era for biopharmaceutical companies. Competition for innovation, ... necessity to keep up with the fast-changing environment ... also influence clinical trials, and clinical trial costs ... effective patient recruitment. Studies conducted by ...
Breaking Medicine Technology:Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 2Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 3Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 4Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 5Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 6Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 7Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 8Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 9Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 10Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 11Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 12Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 13Methodist Children's Hospital In San Antonio, TX Only Hospital In The U.S. Treating Rare Vascular Condition With Dual Wave-Length Laser 2Patient Recruitment in Asia Biotech and Pharma Companies 2Patient Recruitment in Asia Biotech and Pharma Companies 3
... from a Phase III,clinical trial evaluating the efficacy ... the treatment of postmenopausal osteoporosis were,presented at the ... Annual Meeting. In the non-inferiority study comparing risedronate ... [Actonel(R) (risedronate sodium,tablets)] increases in bone mineral density ...
... Medical,Technologies, Inc. (Nasdaq: RMTI ), a ... specialty pharmaceuticals focused on the end-,stage-renal-disease market ... in its Phase IIb dose-ranging study for ... drug. The Phase IIb dose-ranging study ...
Cached Medicine Technology:New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 2New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 3New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 4New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 5New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 6Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 2Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 3Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 4
(Date:9/18/2014)... 2014 Reduce bags under the eyes, ... for these issues in a serum. , "Our Face ... says Kathy Heshelow, founder of Sublime Beauty®. "Each works ... collagen, to improve the eye area." , Today ... wrinkles, dark circles and bags at Amazon with coupon ...
(Date:9/18/2014)... September 18, 2014 Kent, WA Chiropractor ... Chiropractic are pleased to announce that Dawn Kelly has agreed ... Dr. Saggau looks forward to Ms. Kelly expanding her ... talents will make her a key contributor. “ Dawn ... educational, professional, and personal experiences that will allow me ...
(Date:9/18/2014)... 2014 Alexandria, VA — The ... 10 more communities have joined the growing ranks of ... accreditation. The decisions bring the number of governmental public ... is the non-profit organization that administers the national public ... the health of the public by advancing the quality ...
(Date:9/18/2014)... (HealthDay News) -- Older people become more physically vulnerable ... balance of stress hormones during bereavement changes with age, ... are grieving are more likely to have weakened immune ... the difficult weeks and months after loss, we can ... abundant type of white blood cell and as such ...
(Date:9/18/2014)... 2014 It’s been just a few short ... pending bunion splint to website visitors, but already the response ... was absolutely delighted. It is perfect and I find it ... them. THANK YOU FOR LISTENING!!!" Another user compared the ... hole used to slip to the end of my toe. ...
Breaking Medicine News(10 mins):Health News:The Secret to Improving Under-Eye Skin: 30% Off Sale and Report on Ingredients Ends Tonight on the Face Whisperer® Advanced Eye Gel 2Health News:Lake Meridian Chiropractic of Kent, WA Announces that Dawn Kelly Has Been Promoted to the Position of Office Manager 2Health News:Ten More Communities Reaping Benefits of National Accreditation 2Health News:Ten More Communities Reaping Benefits of National Accreditation 3Health News:Ten More Communities Reaping Benefits of National Accreditation 4Health News:Grief Can Weigh on Immune System in Older Folks, Study Says 2Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 2Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 3
... taking too much supplemental calcium are on the rise, ... of the Journal of the American Society Nephrology ... calcium-alkali syndrome is growing in large part because of ... The milk-alkali syndrome arose in the early 1900s ...
... rural southern Asia are exposed every day to unsafe levels ... doubles their risks for cancer, causes cardiovascular disease, and inhibits ... The World Health Organization (WHO) has referred to the situation ... as "the largest mass poisoning of a population in history." ...
... Experts are now recommending that low-dose aspirin therapy to prevent ... younger than 50 and women younger than 60, who have ... aspirin. The new recommendations are based on an analysis ... side effects such as stomach bleeding, and to a much ...
... found if young adults were more fit, 34% of high ... (HealthDay News) -- Low levels of physical activity and fitness ... 20-year study of young adults shows. , The study, released ... print issue of the journal Hypertension , found that ...
... to play in disease detection , TUESDAY, June 1 (HealthDay ... signs of prostate cancer in human urine, adding to the ... friend. , Some scientists have questioned similar reports of dogs ... lead author of this latest study said the findings are ...
... patients who,ve been told to rest and avoid exercise can ... both during and after treatment, according to new national guidelines. ... Biostatistics and a member of the Abramson Cancer Center at ... guidelines at an educational session at the 2010 meeting of ...
Cached Medicine News:Health News:Calcium supplements: too much of a good thing? 2Health News:Researchers offer solutions to poisonous well-water crisis in southern Asia 2Health News:Researchers offer solutions to poisonous well-water crisis in southern Asia 3Health News:Aspirin recommendations changed for many younger diabetic patients 2Health News:Being Young and Sedentary Raises Hypertension Risk Later 2Health News:Being Young and Sedentary Raises Hypertension Risk Later 3Health News:Dog Sniffs Out Prostate Cancer in Small Study 2Health News:New cancer guidelines: Exercise during and after treatment is now encouraged 2Health News:New cancer guidelines: Exercise during and after treatment is now encouraged 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: